159 related articles for article (PubMed ID: 25267360)
1. Cost-utility analysis of oral anticoagulants for nonvalvular atrial fibrillation patients at the police general hospital, Bangkok, Thailand.
Jarungsuccess S; Taerakun S
Clin Ther; 2014 Oct; 36(10):1389-94.e4. PubMed ID: 25267360
[TBL] [Abstract][Full Text] [Related]
2. Cost-Effectiveness Analysis of Direct-Acting Oral Anticoagulants for Stroke Prevention in Thai Patients with Non-Valvular Atrial Fibrillation and a High Risk of Bleeding.
Rattanachotphanit T; Limwattananon C; Waleekhachonloet O; Limwattananon P; Sawanyawisuth K
Pharmacoeconomics; 2019 Feb; 37(2):279-289. PubMed ID: 30387074
[TBL] [Abstract][Full Text] [Related]
3. Cost effectiveness of novel oral anticoagulants for stroke prevention in atrial fibrillation depending on the quality of warfarin anticoagulation control.
Janzic A; Kos M
Pharmacoeconomics; 2015 Apr; 33(4):395-408. PubMed ID: 25512096
[TBL] [Abstract][Full Text] [Related]
4. Cost-Effectiveness of High-Dose Edoxaban Compared with Adjusted-Dose Warfarin for Stroke Prevention in Non-Valvular Atrial Fibrillation Patients.
Nguyen E; Egri F; Mearns ES; White CM; Coleman CI
Pharmacotherapy; 2016 May; 36(5):488-95. PubMed ID: 27015873
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of warfarin care bundles and novel oral anticoagulants for stroke prevention in patients with atrial fibrillation in Thailand.
Ng SS; Nathisuwan S; Phrommintikul A; Chaiyakunapruk N
Thromb Res; 2020 Jan; 185():63-71. PubMed ID: 31770689
[TBL] [Abstract][Full Text] [Related]
6. Anticoagulation Therapy for Atrial Fibrillation in Patients With Alzheimer's Disease.
Ruiz Vargas E; Sposato LA; Lee SAW; Hachinski V; Cipriano LE
Stroke; 2018 Dec; 49(12):2844-2850. PubMed ID: 30571418
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of dabigatran versus vitamin K antagonists for the prevention of stroke in patients with atrial fibrillation: a French payer perspective.
Chevalier J; Delaitre O; Hammès F; de Pouvourville G
Arch Cardiovasc Dis; 2014; 107(6-7):381-90. PubMed ID: 24973113
[TBL] [Abstract][Full Text] [Related]
8. Cost-Effectiveness Analysis of Non-Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Thai Patients With Non-Valvular Atrial Fibrillation.
Dilokthornsakul P; Nathisuwan S; Krittayaphong R; Chutinet A; Permsuwan U
Heart Lung Circ; 2020 Mar; 29(3):390-400. PubMed ID: 31000364
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the cost-effectiveness of new oral anticoagulants for the prevention of stroke and systemic embolism in atrial fibrillation in a UK setting.
Zheng Y; Sorensen SV; Gonschior AK; Noack H; Heinrich-Nols J; Sunderland T; Kansal AR
Clin Ther; 2014 Dec; 36(12):2015-2028.e2. PubMed ID: 25438722
[TBL] [Abstract][Full Text] [Related]
10. Cost-Effectiveness of Left Atrial Appendage Closure for Stroke Reduction in Atrial Fibrillation: Analysis of Pooled, 5-Year, Long-Term Data.
Reddy VY; Akehurst RL; Gavaghan MB; Amorosi SL; Holmes DR
J Am Heart Assoc; 2019 Jul; 8(13):e011577. PubMed ID: 31230500
[TBL] [Abstract][Full Text] [Related]
11. Stroke prevention in patients with atrial fibrillation in France: comparative cost-effectiveness of new oral anticoagulants (apixaban, dabigatran, and rivaroxaban), warfarin, and aspirin.
Lanitis T; Cotté FE; Gaudin AF; Kachaner I; Kongnakorn T; Durand-Zaleski I
J Med Econ; 2014 Aug; 17(8):587-98. PubMed ID: 24831811
[TBL] [Abstract][Full Text] [Related]
12. Cost-Effectiveness of Apixaban versus Warfarin in Chinese Patients with Non-Valvular Atrial Fibrillation: A Real-Life and Modelling Analyses.
Li X; Tse VC; Lau WC; Cheung BM; Lip GY; Wong IC; Chan EW
PLoS One; 2016; 11(6):e0157129. PubMed ID: 27362421
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of new oral anticoagulants compared with warfarin in preventing stroke and other cardiovascular events in patients with atrial fibrillation.
Coyle D; Coyle K; Cameron C; Lee K; Kelly S; Steiner S; Wells GA
Value Health; 2013 Jun; 16(4):498-506. PubMed ID: 23796283
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of rivaroxaban versus warfarin for stroke prevention in atrial fibrillation in the Belgian healthcare setting.
Kleintjens J; Li X; Simoens S; Thijs V; Goethals M; Rietzschel ER; Asukai Y; Saka Ö; Evers T; Faes P; Vansieleghem S; De Ruyck M
Pharmacoeconomics; 2013 Oct; 31(10):909-18. PubMed ID: 24030788
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in patients with atrial fibrillation and prior stroke or transient ischemic attack.
Kamel H; Johnston SC; Easton JD; Kim AS
Stroke; 2012 Mar; 43(3):881-3. PubMed ID: 22308255
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation.
Freeman JV; Zhu RP; Owens DK; Garber AM; Hutton DW; Go AS; Wang PJ; Turakhia MP
Ann Intern Med; 2011 Jan; 154(1):1-11. PubMed ID: 21041570
[TBL] [Abstract][Full Text] [Related]
17. Pharmacogenetic-guided selection of warfarin versus novel oral anticoagulants for stroke prevention in patients with atrial fibrillation: a cost-effectiveness analysis.
You JH
Pharmacogenet Genomics; 2014 Jan; 24(1):6-14. PubMed ID: 24168919
[TBL] [Abstract][Full Text] [Related]
18. Cost effectiveness of rivaroxaban for stroke prevention in German patients with atrial fibrillation.
Mensch A; Stock S; Stollenwerk B; Müller D
Pharmacoeconomics; 2015 Mar; 33(3):271-83. PubMed ID: 25404426
[TBL] [Abstract][Full Text] [Related]
19. Should hemodialysis patients with atrial fibrillation undergo systemic anticoagulation? A cost-utility analysis.
Quinn RR; Naimark DM; Oliver MJ; Bayoumi AM
Am J Kidney Dis; 2007 Sep; 50(3):421-32. PubMed ID: 17720521
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with atrial fibrillation at high risk of bleeding and normal kidney function.
Hernandez I; Smith KJ; Zhang Y
Thromb Res; 2017 Feb; 150():123-130. PubMed ID: 27771008
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
